178 related articles for article (PubMed ID: 22199313)
1. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy.
Pepe P; Aragona F
Anticancer Res; 2011 Dec; 31(12):4445-9. PubMed ID: 22199313
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
3. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients.
Barbera M; Pepe P; Paola Q; Aragona F
Arch Ital Urol Androl; 2012 Dec; 84(4):227-9. PubMed ID: 23427750
[TBL] [Abstract][Full Text] [Related]
4. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
5. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?
Pepe P; Fraggetta F; Galia A; Skonieczny G; Aragona F
Int Braz J Urol; 2012; 38(4):489-95. PubMed ID: 22951161
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
7. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients.
Goode RR; Marshall SJ; Duff M; Chevli E; Chevli KK
Prostate; 2013 Jan; 73(1):48-53. PubMed ID: 22585386
[TBL] [Abstract][Full Text] [Related]
8. Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy?
Pepe P; Fraggetta F; Galia A; Aragona F
Urol Int; 2012; 89(2):143-7. PubMed ID: 22868485
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
[TBL] [Abstract][Full Text] [Related]
10. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
11. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
12. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
[TBL] [Abstract][Full Text] [Related]
13. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
[TBL] [Abstract][Full Text] [Related]
14. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
15. Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy?
Pepe P; Aragona F
Urol Int; 2011; 87(2):171-4. PubMed ID: 21778685
[TBL] [Abstract][Full Text] [Related]
16. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
[TBL] [Abstract][Full Text] [Related]
17. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
19. [Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].
Vlaeminck-Guillem V; Campos-Fernandes JL; Champetier D; Chikh K; Decaussin-Petrucci M; Devonec M; Gobeaux N; Paparel P; Perrin P; Rodriguez-Lafrasse C; Ruffion A
Ann Biol Clin (Paris); 2011; 69(1):31-9. PubMed ID: 21463993
[TBL] [Abstract][Full Text] [Related]
20. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.
Pepe P; Aragona F
Urology; 2007 Dec; 70(6):1131-5. PubMed ID: 18158033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
